ClinicalTrials.gg
RecruitingNCT06104631RelieveUpdated May 2, 2025

A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms

An interventional study of BK003 and Placebo in Irritable Bowel Syndrome-like Symptoms and Crohn Disease Remission, sponsored by Biokuris s.a.. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by Biokuris s.a. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 194 studies in Crohn Disease with a site in Belgium — 41 open to participants now, 56 under way, 29 of them phase 3. Crohn Disease · Belgium.

Planned enrollment
147th of 175
50 · median 211
Started
2024
with 16 others
No phase
12 of 194
8 open now
Primary completion
2025-08
later than 5 of 55 live
Registered
163rd of 194
by date

Among the 194 studies in Crohn Disease with a site in Belgium, this one is the 147th largest by planned enrollment of the 175 interventional ones that give a count, is one of 17 that started in 2024, is one of 12 with no phase, reaches primary completion later than 5 of the 55 other live ones, and was the 163rd registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

41 of the 194 studies in Crohn Disease with a site in Belgium are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies in Crohn Disease with a site in Belgium, or all of them as a file.
02

Study summary

Crohn's disease is a chronic and complex inflammatory bowel disease affecting the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, and fatigue. While its exact cause is unclear, it involves genetic, environmental, and immunological factors. Crohn's disease can lead to nutrient deficiencies and has unpredictable flare-ups and remission periods. During the remission phases, irritable bowel syndrome (IBS)-like symptoms can persist in 50% of patients, for which no satisfactory treatment is available yet.

Chitin-glucan is prebiotic, obtained by extraction, isolation and purification from a fungal resource: the mycelium of Aspergillus niger (a microscopic fungus of the Ascomycetes family) of which it composes the cell walls. The biopolymer consists essentially of two types of polysaccharide chains: chitin (poly-N-acetyl-D-glucosamine) and beta-(1,3)-D-glucan (D-glucose units linked essentially via beta-1,3 bonds). Because of its beta bond, human intestinal enzymes cannot digest it, as a result, the majority of chitin-glucan can reach the colon where it can be fermented by the microbiota.

By modulating the composition and/or activity of the intestinal microbiota, fermentation of chitin-glucan could have beneficial effects on health.

The aim of the RELIEVE study is to assess if BK003 could improve the relief of global symptoms, individual symptoms, stool consistency and frequency of evacuations, quality of life, anxiety, and depression in patients with Crohn's disease in remission without treatment or with stable maintenance therapy and having IBS-like symptoms and to confirm the product's safety.

03

Conditions studied

  • Irritable Bowel Syndrome-like Symptoms
  • Crohn Disease Remission

Keywords

  • chitin-glucan
  • Crohn
  • IBS
  • Irritable Bowel Syndrome-like
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients aged from 18 years to 75 years,
  • Long standing (>3 months prior to V1) -free clinical remission Crohn's disease according to clinical and biochemical assessments,
  • Clinical remission (according to the investigator),
  • Absence of inflammatory markers at V1,
  • Presence of IBS-like symptoms according to Rome IV criteria,
  • Likert scale ≥ 3 for abdominal pain at V0,
  • Patient with correct and complete reporting of the study questionnaires and scores during the run-in period (≥ 75% completion),
  • To continue all medication used in the last month before inclusion at the same dosage,
  • Anti-spasmodic, hypomotility agents, probiotics, prebiotics, bile-acid chelators, and anti-depressants are authorized if consumed for longer than 1 month before inclusion and maintained at a stable dosage for the entire study duration,
  • Agreeing to maintain their lifestyle behaviours during the participation in the study,
  • Patient has read, understood, and signed the form (ICF),
  • Patients capable of communicating with the investigator, replying to the questionnaires, and understanding the requirements and constraints of the study protocol,
  • Possession of a digital device (i.e., smartphone or tablet),
  • Patient willing to adhere to the study visit schedule and able to understand and comply with protocol requirements and product administration,
  • Male or female patient of who agrees to use acceptable methods of (oral, transdermal, systemic contraception, intrauterine device, condom) for the duration of the study,
  • Patient can read and write in French.

Exclusion criteria

Exclusion Criteria:

  • Patients with other concomitant organic gastrointestinal abnormalities besides Crohn's disease: ano-perineal lesions, extra-intestinal manifestations of Crohn's disease, colorectal history of cancer or abdominal radiotherapy, symptomatic intestinal stenosis, substance dependence history,
  • Patients with significant comorbidities: instable cardiovascular diseases, complicated diabetes, instable thyroid function,
  • Patients receiving non-steroidal anti-inflammatory drugs, , opioids, or narcotic analgesics in the last month before V0,
  • Patients beginning a diet or a specific treatment for functional symptoms (probiotics, prebiotics, anti spasmodic, chelators, anti-depressants, etc.) within one month before V1,
  • Ongoing antibiotics or antibiotics prescribed in the last 2 weeks before V1.
  • Excessive alcohol consumption (>30 g/day [i.e., 3 units/day] for men and >20 g/day [i.e., 2 units/day] for women) and/or drug abuse,
  • Pregnancy and lactation, or plan to become pregnant during the study period,
  • Participation in other studies involving or marketed products concomitantly or less than 3 months prior to V0,
  • Known to any of the ingredients or of the study products,
  • Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    BK003

    Dietary Supplement: BK003 The product is a combination of chitin-glucan and micronutrients. The dose of chitin-glucan is 3 g/day. The product is provided as sachets containing powder to be dissolved in a glass of water (about 250 ml) and taken orally.

    Other: BK003

  • Placebo comparator
    Placebo

    Dietary Supplement: BK003 placebo The placebo product has the same composition in excipient, same form and same posology as BK003.

    Other: Placebo

Interventions

  • OtherBK003

    The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.

  • OtherPlacebo

    The placebo product has the same composition in excipient, same form and same posology as BK003.

06

What researchers measure

Primary outcomes

  1. Subject's global assessment (SGA)

    Subjective global assessment of relief responder rate. SGA is scored on a 5-point Likert scale (1 = completely relieve and 5= being worse). Patients with an SGA of relief score from 1 to 3 is considered as responder.

    Time frame: at week 4 after randomization on period I (cross over) and at week 4 after wash-out period II (cross over)

Secondary outcomes

  1. Individual symptoms

    Weekly change from baseline in mean 7-point Likert scale for each of the symptoms: abdominal pain, abdominal bloating, flatulence. Scores of each symptoms will be assessed (from 1= none to 7= very severe) every day and mean scores of each symptoms will be calculated every week of the treatment period I \& II and compared with baseline (run-in period).

    Time frame: weekly from randomization up to the end of the study (week 10 post run in)

  2. Stool consistency & dyschesia

    Weekly change from baseline on number of normal stool. BSS score, including dyschesia, will be assessed every day and mean scores will be calculated every week until the end of the study

    Time frame: weekly from randomization up to the end of the study (week 10 post run in)

  3. Stool number

    Weekly change from baseline on number of evacuations per day. The mean daily number of bowel movements will be calculated for each week until the end of the study

    Time frame: weekly from randomization up to the end of the study (week 10 post run in period)

  4. IBS-related quality of life

    The absolute and relative change of IBS-related quality of life score.

    Time frame: At week 0, week 4, week 6, week 10 post-run in period

  5. Anxiety and depression

    The absolute and relative change of anxiety and depression (HADS score)

    Time frame: At week 0, week 4, week 6, week 10 post-run in period

  6. Serum CRp & fecal calprotectine

    Change from baseline for the following measures : serum CRP, fecal calprotectine, alpha diversity and the relative abundance of bacterial, viral and fungal taxa in stools

    Time frame: at week 4 versus week 0 (period I) and at week 10 versus week 6 (period II) post run in period

  7. Adverse events

    Occurence and severity of adverse events

    Time frame: At week 0, week 4, week 6, week 10 post-run in period

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Aug 2025, 17 months after the start.

Of 302 interventional studies with no phase under Crohn Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 65. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 27, 2023
StartActual
Mar 12, 2024
Primary completionEst.
Aug 2025
CompletionEst.
Oct 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06104631
Lead sponsor
Biokuris s.a.
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Mar 12, 2024
Primary completion
Aug 2025 (estimated)
Completion
Oct 2025 (estimated)
Last update
May 2, 2025

Study contacts

Salvatore Modica
Contact
s.modica@biokuris.com
+32 4 259 85 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion